Insmed Incorporated

INSM · Nasdaq · United States

Share price · INSM

$119.80-8.66 (-6.74%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.9M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when INSM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Oct 2026+15.1%
  2. 6 Aug 2026+33.9%
  3. 5 Jun 2026-10.2%
  4. 12 May 2026+11.7%
  5. 7 May 2026-23.4%

    Nothing announced by INSM that day or the session before.

  6. 24 Apr 2026-6.0%
  7. 23 Mar 2026+5.9%
  8. 19 Feb 2026+6.5%
  9. 21 Jan 2026-4.4%
  10. 18 Dec 2025-16.1%

Share of unusual movement by asset

For each asset, the share of INSM's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—39%
Sessions with no dated event—61%

No dated announcements about its assets since 14 Oct 2025.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2
Stem cell factor (SCF / KIT ligand)Monoclonal antibody
Atopic DermatitisAsthma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$524M$270M$397M+ $750M short-term inv.$100M-$36M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$425M$210M$545M+ $616M short-term inv.$13M-$89M operating cash flowreport ↗
2026-Q1$306M$209M$582M+ $641M short-term inv.$164M-$223M operating cash flowreport ↗
2025-Q3$142M$186M$335M+ $1.3B short-term inv.$370M-$220M operating cash flowreport ↗
2025-Q2$107M$177M$1.3B+ $572M short-term inv.$322M-$206M operating cash flowreport ↗
2025-Q1$93M$153M$403M+ $796M short-term inv.$257M-$262M operating cash flowreport ↗
2024-Q3$93M$151M$461M+ $1.0B short-term inv.$221M-$181M operating cash flowreport ↗
2024-Q2$90M$147M$1.2B+ $0 short-term inv.$301M-$123M operating cash flowreport ↗
2024-Q1$76M$121M$596M+ $0 short-term inv.$157M-$184M operating cash flowreport ↗
2023-Q3$79M$109M$487M+ $299M short-term inv.$159M-$136M operating cash flowreport ↗
2023-Q2$77M$197M$613M+ $305M short-term inv.$245M-$123M operating cash flowreport ↗
2023-Q1$65M$128M$969M+ $30M short-term inv.$160M-$146M operating cash flowreport ↗
2022-Q3$68M$100M$415M+ $99M short-term inv.$131M-$90M operating cash flowreport ↗
2022-Q2$65M$89M$416M+ $139M short-term inv.$96M-$102M operating cash flowreport ↗
2022-Q1$53M$84M$516M+ $119M short-term inv.$95M-$105M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$606M$771M$510M+ $920M short-term inv.$319M-$935M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$364M$598M$555M+ $879M short-term inv.$228M-$684M operating cash flowreport ↗
2023-FY$305M$571M$482M+ $298M short-term inv.$187M-$536M operating cash flowreport ↗
2022-FY$245M$398M$1.1B+ $74M short-term inv.$120M-$400M operating cash flowreport ↗
2021-FY$188M$273M$717M+ $0 short-term inv.$109M-$363M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 147 sales ($133.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-19Koppikar Utpal · directorAward / grant6,139——Form 4
2026-10-19Hudson Paul · directorAward / grant6,139——Form 4
2026-09-09Brennan David R · directorOpen-market sale25,000$124.00$3.1MForm 4
2026-08-17SHAROKY MELVIN MD · directorOpen-market sale5,000$127.53$638KForm 4
2026-08-10Adsett Roger · Chief Operating OfficerOption exercise82,280$13.67$1.1MForm 4
2026-08-10Adsett Roger · Chief Operating OfficerOption exercise76,600$17.16$1.3MForm 4
2026-08-10Adsett Roger · Chief Operating OfficerOption exercise80,970$30.46$2.5MForm 4
2026-08-10Adsett Roger · Chief Operating OfficerOpen-market sale239,850$133.27$32.0MForm 4